Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Misoprostol for induction of labour to terminate pregnancy in the second or third trimester for women with a fetal anomaly or after intrauterine fetal death|
|Citation:||The Cochrane Database of Systematic Reviews, 2010; 2010(4):004901-1-004901-122|
|Publisher:||Update Software Ltd|
|Jodie M Dodd and Caroline A Crowther|
|Abstract:||Background A woman may need to give birth prior to the spontaneous onset of labour in situations where the fetus has died in utero (also called a stillbirth), or for the termination of pregnancy where the fetus, if born alive would not survive or would have a permanent handicap. Misoprostol is a prostaglandin medication that can be used to induce labour in these situations. Objectives To compare the benefits and harms of misoprostol to induce labour to terminate pregnancy in the second and third trimester for women with a fetal anomaly or after intrauterine fetal death when compared with other methods of induction of labour. Search strategy We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (November 2009). Selection criteria Randomised controlled trials comparing misoprostol with placebo or no treatment, or any other method of induction of labour, for women undergoing induction of labour to terminate pregnancy in the second and third trimester following an intrauterine fetal death or for fetal anomalies. Data collection and analysis Both authors independently assessed trial quality and extracted data. Main results We included 38 studies (3679 women). Nine studies included pregnancies after intrauterine deaths, five studies included termination of pregnancies because of fetal anomalies when the fetus was still alive and the rest (24) presented the pooled data for intrauterine deaths, fetal anomalies and social reasons. When compared with agents that have traditionally been used to induce labour in this setting (for example, gemeprost, prostaglandin E2 and prostaglandin F2alpha), vaginal misoprostol is as effective in ensuring vaginal birth within 24 hours, with a similar induction to birth interval. Vaginal misoprostol is associated with a reduction in the occurrence of maternal gastrointestinal side effects such as nausea, vomiting and diarrhoea when compared with other prostaglandin preparations. While the different treatments involving various prostaglandin preparations appear comparable for the reported outcomes, the information available regarding rare maternal complications, such as uterine rupture, is limited.|
|Keywords:||Humans; Fetal Death; Abortifacient Agents, Nonsteroidal; Oxytocics; Misoprostol; Abortion, Induced; Labor, Induced; Pregnancy; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Female; Congenital Abnormalities; Randomized Controlled Trials as Topic|
|Rights:||Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.|
|Appears in Collections:||Obstetrics and Gynaecology publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.